The Institute of Cancer Research, London, is one of the world’s most influential cancer research organisations. Today, discover new weaknesses in cancer cells, learn how 'junk DNA' is linked to cancer risk and find out how you can support our work.
Professor Ros Eeles talks about the discovery that prostate cells that look normal under the microscope may be hiding genetic mutations that could develop into cancer.
The Telegraph has published a letter written by the ICR – and co-signed by more than 10 charities – that calls for urgent reform to the rules for testing new drugs in children and young people.
Scientists have developed a new test – based on software used in criminology – to analyse immune system 'hotspots' in breast cancer tumours.
Genome analysis at our Tumour Profiling Unit – discovering cancer’s weaknesses
Pioneering phase I studies of new cancer drugs
How mouse 'avatars' could help tailor cancer treatments in head and neck cancers
Personalising treatments for patients on clinical trials
Developing new drugs for hard-to-treat childhood cancers
Our PhD students conduct world-class research projects, while our MSc in Clinical Oncology teaches about the latest in clinical practice.
Our Chief Executive and President, Professor Paul Workman, shares his experiences on his blog, The Drug Discoverer.
The ICR’s research aims to learn more about cancer genetics and tumour biology – and use that information in discovering new treatments.
Your support can help us fight an often overlooked form of cancer, one that claims an increasingly large number of lives every year.
We work in close partnership with industry to take results into the clinic as soon as possible, and make sure our research delivers for cancer patients.
The ICR is the top-ranked academic research centre in the UK after coming first overall in the 2014 Research Excellence Framework.
In modern cancer treatment, are two drugs better than one?
Sandwiches, the pancreas and cancer’s bullying of healthy cells
Panorama’s behind the scenes glimpse at how science benefits cancer patients – and vice versa
Prof Paul Workman wrote about prioritising innovation during drug development in @Pharmafocus (pages 4 and 5 http://t.co/0lneLqe417)